The aryl hydrocarbon receptor (AHR), highly expressed in the liver, was originally defined as a xenobiotic receptor that regulates xenobiotic metabolism. Subsequent studies suggest that AhR also has endobiotic functions by affecting physiology and tissue development. In the previous funding period, we have shown that activation of AhR caused spontaneous fatty liver and sensitized mice to methione and choline deficient diet- induced nonalcoholic steatohepatitis. However, whether and how AhR affects dietary induced fatty liver and associated metabolic syndrome such as obesity and insulin resistance remains largely unknown. The fibroblast growth factor 21 (FGF21), produced predominantly in the liver, is a systemic insulin sensitizer. FGF21 exhibits many metabolic benefits, ranging from reducing body weight to alleviation of hyperglycemia and insulin resistance, and improvement of lipid profiles. Although FGF21 was shown to be regulated by the AHR agonist TCDD, the pathophysiological relevance of this regulation remains to be defined. Our preliminary results showed that: 1) Tetracycline inducible transgenic mice expressing the constitutively activated human AHR (CA-AHR) in the liver have been created; 2) CA-AHR transgenic mice showed protection from high-fat diet (HFD) induced obesity and insulin resistance despite having severe fatty liver; 3) Although the transgene was targeted to the liver, CA-AHR transgenic mice exhibited metabolic benefits in extrahepatic tissues, such as the adipose tissue and skeletal muscle; 4) The pleiotropic benefit of AHR activation was associated with the induction of FGF21, and adenoviral knockdown of FGF21 abolished the metabolic benefit of the CA-AHR transgene; 5) FGF21 is a transcriptional target of AHR; 6) The endogenous AhR agonist 6-formy-indolo[3,2-b] carbazole (FICZ) activated AhR efficiently; 7) CA-AHR transgenic mice up to 28 weeks of age did not show signs of spontaneous non-alcoholic steatohepatitis (NASH); and 8) The CA-AHR transgene showed a tendency to reverse the pre-existing insulin resistance. Based on our preliminary data, we hypothesize that the xenobiotic receptor AHR has a previously unrecognized hepatic function in regulating energy metabolism and insulin sensitivity by forming the AHR-FGF21 signaling axis. Specifically, we hypothesize that activation of AHR disassociates fatty liver from insulin resistance and provides metabolic benefits by transcriptionally activating the FGF21 gene. We propose three specific aims to test our hypotheses: 1) To determine whether pharmacological activation of AHR confers metabolic benefits and disassociates fatty liver from insulin resistance; 2) To determine whether genetic and pharmacological activation of AhR relieves pre-existing obesity and insulin resistance; 3) To determine whether FGF21 is necessary for the metabolic benefit of AHR. To our knowledge, the current study represents the first attempt to systematically determine the role of AhR in diet-induced metabolic abnormalities. The tetracycline inducible human AHR transgenic mice represent a unique gain of function model to understand the endobiotic function of AHR without the concern of the toxicity. The AHR-FGF21 axis of endocrine signaling pathway establishes AHR as a pivotal environmental modifier that integrates signals from chemical exposure in the regulation of lipid and energy metabolism. Our results also suggest that development of non-toxic AHR agonists may be a novel approach in managing metabolic syndrome.

Public Health Relevance

The aryl hydrocarbon receptor (AHR), highly expressed in the liver, was originally defined as a xenobiotic receptor that regulates xenobiotic metabolism. The goal of this study is to determine whether and how AhR affects dietary induced fatty liver and associated metabolic syndrome such as obesity and insulin resistance. We hypothesize that the 'xenobiotic receptor' AHR has a previously unrecognized hepatic function in regulating energy metabolism and insulin sensitivity by forming the AHR-FGF21 signaling axis. Specifically, we hypothesize that activation of AHR disassociates fatty liver from insulin resistance and provides metabolic benefits by transcriptionally activating the FGF21 gene. The AHR-FGF21 axis of endocrine signaling pathway establishes AHR as a pivotal environmental modifier that integrates signals from chemical exposure in the regulation of hepatic and extrahepatic lipid and energy metabolism. Our results also suggest that development of non-toxic AHR agonists may be a novel approach in managing metabolic syndrome.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK083952-09
Application #
9670091
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Doo, Edward
Project Start
2010-05-01
Project End
2020-03-31
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
9
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15260
Bi, Yuhan; Jiang, Mengxi; Guo, Weiwei et al. (2018) Sex-Dimorphic and Sex Hormone-Dependent Role of Steroid Sulfatase in Adipose Inflammation and Energy Homeostasis. Endocrinology 159:3365-3377
Bi, Yuhan; Shi, Xiongjie; Zhu, Junjie et al. (2018) Regulation of Cholesterol Sulfotransferase SULT2B1b by Hepatocyte Nuclear Factor 4? Constitutes a Negative Feedback Control of Hepatic Gluconeogenesis. Mol Cell Biol 38:
Garbacz, Wojciech G; Uppal, Hirdesh; Yan, Jiong et al. (2018) Chronic Activation of Liver X Receptor Sensitizes Mice to High Cholesterol Diet-Induced Gut Toxicity. Mol Pharmacol 94:1145-1154
Choi, You-Jin; Zhou, Dong; Barbosa, Anne Caroline S et al. (2018) Activation of Constitutive Androstane Receptor Ameliorates Renal Ischemia-Reperfusion-Induced Kidney and Liver Injury. Mol Pharmacol 93:239-250
Niu, Yongdong; Xu, Meishu; Slagle, Betty L et al. (2017) Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis. Hepatology 65:893-906
Garbacz, Wojciech G; Jiang, Mengxi; Xu, Meishu et al. (2017) Sex- and Tissue-Specific Role of Estrogen Sulfotransferase in Energy Homeostasis and Insulin Sensitivity. Endocrinology 158:4093-4104
Jiang, Mengxi; Xu, Meishu; Ren, Songrong et al. (2017) Transgenic Overexpression of Steroid Sulfatase Alleviates Cholestasis. Liver Res 1:63-69
Garbacz, Wojciech G; Lu, Peipei; Miller, Tricia M et al. (2016) Hepatic Overexpression of CD36 Improves Glycogen Homeostasis and Attenuates High-Fat Diet-Induced Hepatic Steatosis and Insulin Resistance. Mol Cell Biol 36:2715-2727
Wei, Yuan; Tang, Chenxiao; Sant, Vinayak et al. (2016) A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism? Curr Pharmacol Rep 2:187-192
Zhao, Zanmei; Xu, Dan; Li, Shuqiang et al. (2016) Activation of Liver X Receptor Attenuates Oleic Acid-Induced Acute Respiratory Distress Syndrome. Am J Pathol 186:2614-22

Showing the most recent 10 out of 35 publications